Null activity of selenium and vitamin E as cancer chemopreventive agents in the rat prostate

Cancer Prevention Research

Volumn 3, Issue 3, 2010, Pages 381-392

  McCormick, David L ^a   Rao, K V N ^a   Johnson, William D ^a   Bosland, Maarten C ^b   Lubet, Ronald A ^c   Steele, Vernon E ^c  

^a IIT RESEARCH INSTITUTE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; LEVO SELENOMETHIONINE; METHIONINE; SELENIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; INCIDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RAT;

ADENOCARCINOMA; ALKYLATING AGENTS; ALPHA-TOCOPHEROL; ANDROGENS; ANIMALS; ANTIOXIDANTS; CYPROTERONE ACETATE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; MALE; METHYLNITROSOUREA; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; SELENIUM COMPOUNDS; SELENOMETHIONINE; TESTOSTERONE; VITAMIN E;

EID: 77949730266     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0176     Document Type: Article

References (51)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.
2. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009;73:S4-10.
3. Sakr WA, Grignon DJ, Haas GP, et al. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995;191:838-41.
4. Sánchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 2003; 54:238-47.
5. Klein EA. Chemoprevention of prostate cancer. Annu Rev Med 2006; 57:49-63.
6. Andriole GL. Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology 2009;73:S36-43.
7. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973;179:588-90.
8. Hoekstra WG. Biochemical function of selenium and its relation to vitamin E. Fed Proc 1975;34:2083-9.
9. Chaudiere J, Wilhelmsen EC, Tappel AL. Mechanism of seleniumglutathione peroxidase and its inhibition by mercaptacarboxylic acids and other mercaptans. J Biol Chem 1984;259:1043-50.
10. Young VR, Nahapetian A, Janghorbani M. Selenium bioavailability with reference to human nutrition. Am J Clin Nutr 1982;35:1076-88.
11. Levander OA. Considerations in the design of selenium bioavailability studies. Fed Proc 1983;42:1721-5.
12. Schrauzer GN, White DA, Schneider CJ. Cancer mortality correlation studies-III: statistical associations with dietary selenium intakes. Bioinorg Chem 1977;7:23-31.
13. Naithani R. Organoselenium compounds in cancer chemoprevention. Mini Rev Med Chem 2008;8:657-68.
14. Birt DF. Update on the effects of vitamins A, C, and E and selenium on carcinogenesis. Proc Soc Exp Biol Med 1986:311-20.
15. Birt DF, Julius AD, Runice CE, Salmasi S. Effects of dietary selenium on bis(2-oxopropyl)nitrosamine-induced carcinogenesis in Syrian golden hamsters. J Natl Cancer Inst 1986;77:1281-6.
16. Birt DR, Julius AD, Runice CE, White LT, Lawson T, Pour PM. Enhancement of BOP-induced pancreatic carcinogenesis in seleniumfed Syrian golden hamsters under specific dietary conditions. Nutr Cancer 1988;11:21-33.
17. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005;64:527-42.
18. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983;2:130-4.
19. Criqui MH, Bangdiwala S, Goodman DS, et al. Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study. Ann Epidemiol 1991;1:385-93.
20. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696-703.
21. Wigle DT, Turner MC, Gomes J, Parent ME. Role of hormonal and other factors in human prostate cancer. J Toxicol Environ Health B Crit Rev 2008;11:242-59.
22. Allen NE, Appleby PN, Roddam AW, et al. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr 2008;88:1567-75.
23. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. Carotene and Retinol Efficacy Trial co-investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1069-76.
24. Peters U, Foster CB, Chatterjee N, et al. Serum selenium and risk of prostate cancer - a nested case-control study. Am J Clin Nutr 2007; 85:209-17.
25. Clark LC, Combs GF, Jr., Turnbull BW, et al, Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 1996;276:1957-63.
26. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4.
27. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9.
28. Peters U, Littman AJ, Kristal AR, Patterson RE, Potter JD, White E. Vitamin E selenium supplementation and risk of prostate cancer in the Vitamins and Lifestyle (VITAL) study cohort. Cancer Causes Control 2008;19:75-87.
29. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 2001;166:1311-5.
30. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
31. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301: 39-51.
32. McCormick DL, Rao KVN, Steele VE, Lubet RA, Kelloff GJ, Bosland MC. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res 1999;59:521-4.
33. McCormick DL, Johnson WD, Bosland MC, Lubet RA, Steele VE. Chemoprevention of rat prostate carcinogenesis by soy isoflavones and Bowman-Birk Inhibitor. Nutr Cancer 2007;57:184-93.
34. Rao KVN, Bosland MC, Lubet RA, Steele VE, Kelloff GJ, McCormick DL. Suppression of rat prostate carcinogenesis by dietary dehydroepiandrosterone. Cancer Res 1999;59:3084-9.
35. McCormick DL, Johnson WD, Kozub NM, et al. Chemoprevention of rat prostate carcinogenesis by 16α-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis 2007;28:398-403.
36. Bosland MC, Prinsen MK, Dirksen TJ, Spit BJ. Characterization of adenocarcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2′-dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res 1990;50:700-9.
37. McCormick DL, Rao KVN, Dooley L, et al. Influence of N-methyl- Nnitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans- retinamide on prostate cancer induction in Wistar (WU) rats. Cancer Res 1998;58:3282-8.
38. Bosland MC. Age-related lesions in male accessory sex glands and penis of the rat. In: Mohr U, et al, editor. Monographs on the pathology of the aging rat, vol. 1. Washington (DC): ILSI Press; 1992, p. 469-72.
39. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 1999;35:459-63.
40. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 1997;20:36-9.
41. Bosland MC, McCormick DL, Melamed J, Walden PD, Zeleniuch-Jacquotte A, Lumey LH. Chemoprevention strategies for prostate cancer. Eur J Cancer Prev 2002;11 Suppl 2:S18-27.
42. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;49:215-24.
43. McCormick DL, Rao KVN. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever (WU) rat. Eur Urol 1999;35: 464-7.
44. Bosland MC, Johnson WD, Steele VE, Lubet RA, Kelloff GJ, McCormick DL. Chemoprevention efficacy evaluation of combined administration of L-selenomethionine + vitamin E in the rat prostate. Proc Am Assoc Cancer Res 2000;41:339-40.
45. McCormick DL, Johnson WD, Lubet RA, Steele VE, Bosland MC. Null activity of selenized yeast as a chemopreventive agent in the rat prostate. Proc Amer Assoc Cancer Res 2003;44:891.
46. Hasunuma R, Ogawa T, Kawanishi Y. Fluorometric determination of selenium in nanogram amounts in biological materials using 2,3-diaminonaphthalene. Anal Biochem 1982;126:242-5.
47. Koh TS, Benson TH. Critical re-appraisal of fluorometric method for determination of selenium in biological materials. J Assoc Off Anal Chem 1983;66:918-26.
48. Driskell WJ, Neese JW, Bryant CC, Bashor MM. Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography. J Chromatogr 1982;231:439-44.
49. Möhring C, Bach P, Kosciesza S, Goepel M. A primary adenocarcinoma of the seminal vesicles. Case report of a rare malignancy. Urologe A 2008;47:616-9.
50. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009;301:52-62.
51. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis 2000;3:145-5.